tirzepatide loss of exclusivity Generic Zepbound Availability & Release Date The Heavy Price of GLP-1

GIP receptor agonism Retatrutide activates glucose-dependent insulinotropic polypeptide (GIP) hormone receptors to enhance insulin secretion and glucose reuptake in cells and slow down gastric emptying

Zepbound, the weight-loss version of Tirzepatide, added $2.31 billion in Q1 sales, bringing the total to $6.15 billion, making it Semaglutides biggest rival and a strong candidate for future top drug status

""Tan jab" is an unlicensed medicine and may not be safe" (Press release)

This temperature range represents standard pharmaceutical refrigeration conditions that prevent molecular degradation while remaining practical for routine laboratory operations and pharmaceutical distribution centers handling multiple product lines simultaneously